Melinda Buntin is Professor and Chair of the Department of Health Policy at Vanderbilt University’s School of Medicine. She previously served as Deputy Assistant Director for Health at the Congressional Budget Office (CBO), where she was responsible for managing and directing studies of health care and health care financing issues in the Health, Retirement, and Long-term analysis Division. Prior to joining CBO, Dr. Buntin worked at the Office of the National Coordinator for Health IT, where she established and directed the economic analysis, evaluation, and modeling group, while on leave from RAND. At RAND, Dr. Buntin served as deputy director of RAND Health’s Economics, Financing, and Organization Program, director of Public Sector Initiatives for RAND Health, and co-director of the Bing Center for Health Economics. Her research at RAND focused on insurance benefit design, health insurance markets, provider payment, and the care use and needs of the elderly. She has an A.B. from the Woodrow Wilson School at Princeton and a Ph.D. in Health Policy with a concentration in economics from Harvard University.

Recent Posts by Melinda Buntin

The 340B Program: Mandatory Reporting, Alternative Eligibility Criteria Should Be Top Priorities For Congress

Previous assessments of the 340B program have largely focused on cherry-picked participants. But DSH hospitals that participate in 340B are quite diverse. A priority for policymakers should be more systematic and timely data on participating DSH hospitals’ 340B revenue and safety-net services.

State Medicaid Lessons For Federal Health Reform

Evidence remains sparse on whether policies to increase enrollee engagement and responsibility have reduced program costs. However, the experience of states with 1115 waivers can offer useful lessons on the design and effectiveness of these types of Medicaid reforms.

Spending Growth Trends: Keeping An Eye On Spending Per Person

All of the evidence points to continued modest growth in per capita/enrollee spending. This is a strong signal that we may be in an era where the “new normal” is more restrained growth in the use of health care services, even as the economic recovery continues and rates of uninsurance decline.